Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to see if timed fasting (periods of time that you don't eat) in participants who are receiving chemotherapy prior to surgery is achievable, safe and can improve quality of life, symptoms and outcomes (results) compared to participants who receive standard dietary recommendations in individuals being treated for epithelial ovarian cancer . The main questions it aims to answer are: * Is it feasible to use intermittent fasting during neoadjuvant chemotherapy? * Is it safe to use intermittent fasting during neoadjuvant chemotherapy? * Do participants find it acceptable to use intermittent fasting during neoadjuvant chemotherapy? Researchers will compare participants who receive standard dietary recommendations to see which method is more achievable, safe, and able to improve quality of life, symptoms and outcomes. Participants will: * Receive either the fasting intervention (schedule of times when you do not eat) or standard diet recommendations for 6-9 weeks prior to your surgery starting with the second cycle of chemotherapy. * All participants will be asked to complete chemotherapy and surgery, cancer imaging, baseline screening tests, nutritional assessments, food diaries, blood tests, and surveys about wellbeing. * Participants in the intervention group will be asked to follow a fasting schedule that consists of not eating for 16 hours a day followed by normal eating for the remaining 8 hours of the day for 5 days in a row followed by 2 days of regular eating each week.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat i więcej
- •Potwierdzony diagnoza pierwotnego raka jajnika (w tym raka jajnowodu i otrzewnej)
- •Pacjenci otrzymujący chemioterapię opartą na platynie na raka jajnika
- •Rak zaawansowany (stopień III lub IV) zaplanowany do chemioterapii przed operacją
- •Pacjenci z nawrotowym rakiem jajnika planowani do chemioterapii
- •Pacjenci po chemioterapii i operacji, którzy będą otrzymywać dodatkową chemioterapię
- •Każdy rodzaj histologiczny raka jajnika
- •Prawidłowe funkcje poznawcze
✗ Disqualifies
- •Wiek poniżej 18 lat
- •Całkowita lub częściowa niedrożność jelit potwierdzona na badaniu obrazowym
- •Niemożność udzielenia świadomej zgody na udział w badaniu
- •Wskaźnik BMI poniżej 18
- •Poważne niedożywienie oceniane przez dietetyka
- •Cukrzyca typu 1 leczona insuliną
- •Brak badania tomografii przed leczeniem lub zbyt duża przerwa od badania do pierwszej chemioterapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 6, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center
Cleveland, United States
Trial contact
Michelle Kuznicki, MD
Jackie Ludwig
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.